Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development

Table of Contents

EXECUTIVE SUMMARY

• Scope and Methodology
• Introduction
• Current Stem Cell Therapies
• Developmental Stem Cell Therapies
• Issues in Stem Cell Research
  • Embryonic Stem Cells
  • Non-Embryonic Stem Cells
• Stem Cell Forecasts

INTRODUCTION

• The Promise of Stem Cells in Medical Treatment
• Types of Stem Cells
• Embryonic Stem Cells
• Important Developments in ES Cell Research
• Adult Stem Cells
• Important Developments in AS Cell Research
• Cord Blood Stem Cells
• Stem Cell Harvesting
  • Embryonic Stem Cells
    • Therapeutic Cloning
  • Unfertilized Eggs
  • Adult Stem Cells
    • Leukapheresis
    • Peripheral Blood
  • Cord Blood Stem Cells
• Transplantation Approaches
• Allogenic Transplantation
• Transplantation Procedures
• Cancerous Stem Cells
  • Other Harmful Stem Cells
• Stem Cells in Drug Development
• Stem Cell Therapeutics
  • Stem Cell Targeting Drugs
  • Stem Cell Generated Organs

CURRENT STEM CELL THERAPIES

• Cancer
• Leukemia
• Gene Therapy

• Multiple Myeloma
• Non-Hodgkin' s Lymphoma
• Noncancerous Diseases
  • Aplastic Anemia
  • Immunodeficiency
  • Lupus
  • Sickle Cell Disease
  • Other Conditions

DEVELOPMENTAL STEM CELL THERAPIES

• Alzheimer' s Disease
• Arthritis
• Burns
• Cancer
• Cardiovascular Conditions
• Critical Limb Ischemia
• Crohn' s Disease
• Diabetes
• Incontinence
• Infertility
• Liver Failure
• Lung Disease
• Multiple Sclerosis
• Orthopedics
• Osteoporosis
• Parkinson' s Disease
• Sickle Cell Disease
• Best Case
  • Stem Cell Therapeutics
  • Fees Related to Drug Development
• Most Likely Case
  • Stem Cell Therapeutics
  • Fees Related to Drug Development
• Worst Case
  • Stem Cell Therapeutics
  • Umbilical Cord Blood Banking
  • Fees Related to Drug Development
• ISSUES IN STEM CELL RESEARCH
  • Ethical Questions
  • Research Funding
    • Federal Funding
    • State Funding
  • International Initiatives
  • Stem Cell Patents

• COMPANY PROFILES
  • Aastrom Biosciences
    • History and Lines of Business
    • Financial Information
    • Stem Cell Technology
  • Advanced Cell Technologies
    • History and Lines of Business
    • Financial Information
    • Stem Cell Technology
  • Brainstorm Cell Therapeutics
    • History and Lines of Business
    • Financial Information
    • Stem Cell Technology
  • Celegene
    • History and Lines of Business
    • Financial Information
    • Stem Cell Technology
  • Cord Blood America
    • History and Lines of Business
    • Financial Information
    • Stem Cell Technology
  • Cord Blood Registry
    • History and Lines of Business
    • Financial Information
    • Stem Cell Technology
  • Cryo-Cell International
    • History and Lines of Business
    • Financial Information
    • Stem Cell Technology
  • ES Cell International
    • History and Lines of Business
    • Financial Information
    • Stem Cell Technology
  • Geron
    • History and Lines of Business
    • Financial Information
    • Stem Cell Technology
  • Harvest Technologies
    • History and Lines of Business
    • Financial Information
    • Stem Cell Technology
  • Invitrogen
    • History and Lines of Business
    • Financial Information
    • Stem Cell Technology
  • Medistem
    • History and Lines of Business
    • Financial Information
    • Stem Cell Technology
  • Neostem
    • History and Lines of Business
    • Financial Information
    • Stem Cell Technology
  • Opexa Therapeutics
    • History and Lines of Business
    • Financial Information
    • Stem Cell Technology
  • Osiris Therapeutics
    • History and Lines of Business
    • Financial Information
    • Stem Cell Technology
  • Plureon
    • History and Lines of Business
    • Financial Information
    • Stem Cell Technology
  • Regenetech
    • History and Lines of Business
    • Financial Information
    • Stem Cell Technology
  • Revivicor
    • History and Lines of Business
    • Financial Information
  • Stem Cell Sciences
    • History and Lines of Business
    • Financial Information
    • Stem Cell Technology
  • StemLifeLine
    • History and Lines of Business
    • Financial Information
    • Stem Cell Technology
  • ThermoGenesis
    • History and Lines of Business
    • Financial Information
    • Stem Cell Technology
  • VetCell Bioscience
    • History and Lines of Business
    • Financial Information
    • Stem Cell Technology
  • ViaCell
    • History and Lines of Business
    • Financial Information
    • Stem Cell Technology

TABLE OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

• Table 1-1: Total Market for Stem Cell Technologies in $ Millions, 2007-2020
• Table 1-2: Stem Cell Therapeutics Market in $ Millions, 2007-2020
• Table 1-3: Total Market for Cord Blood Banking Fees in $ Millions, 2007-2020
• Table 1-4: Total Market for Stem Cell Drug Development Technologies in $ Millions, 2007-2020

CHAPTER THREE: CURRENT STEM CELL THERAPIES

• Table 3-1: Types of Leukemia, 2007

CHAPTER FOUR: DEVELOPMENTAL STEM CELL THERAPIES

• Table 4-1: Global Disease Populations Addressed by Potential Stem Cell Therapies, 2007
• Table 4-2: Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2007 and 2020
• Table 4-3: Estimated and Projected World Cancer Mortality by Selected Types of Cancer, 2007 and 2020
• Table 4-4: Types and Features of Urinary Incontinence, 2007 vTable 4-5: Types and Causes of Male Infertility, 2007
• Table 4-6: Common Diseases of the Lungs, 2007

CHAPTER FIVE: MARKET ANALYSIS

• Table 5-1: Persons Affected by Key Stem Cell Therapeutic Targets in Millions, 2007
• Table 5-2: Best Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2007 - 2020
• Table 5-3: Best Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2007 - 2020
• Table 5-4: Best Case: Cord Blood Banking Revenues in $ Millions, 2007-2020
• Table 5-5: Best Case: Stem Cell-Based Drug Development Technology Fees, 2007-2020 (Preclinical Drug Candidates, Cost of Testing, Utilization of New Technology, Cost of New Technolgy per Drug)
• Table 5-6: Best Case: Stem Cell-Based Drug Development Technology Fees in $ Millions, 2007-2020
• Table 5-7: Most Likely Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2007 - 2020
• Table 5-8: Most Likely Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2007-2020
• Table 5-9: Most Likely Case: Cord Blood Banking Revenues in $ Millions, 2007-2020
• Table 5-10: Most Likely Case: Stem Cell-Based Drug Development Technology Fees in $ Millions, 2007-2020
• Table 5-11: Most Likely Case: Stem Cell-Based Drug Development Technology Fees in $ Millions, 2007-2020
• Table 5-12: Worst Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2007 - 2020
• Table 5-13: Worst Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2007-2020
• Table 5-15: Worst Case: Stem Cell-Based Drug Development Technology Fees in $ Millions, 2007-2020
• Table 5-16: Worst Case: Stem Cell-Based Drug Development Technology Fees in $ Millions, 2007-2020

ISSUES IN STEM CELL RESEARCH

• Table 6-1: NIH Funding for Stem Cell Research in $ Million, 2003-2008 (est.)
• Table 6-2: Positions on Human ES Cell Research by Country, 2007

COMPANY PROFILES

• Table 7-1: Main Activities of Selected Stem Cell Companies, 2007
• Table 7-2: Therapeutic Focus of Selected Stem Cell Therapeutics Companies, 2007